General

“The COVID-19 impact was not all bad” – European Biotechnology | Vol. 19 2020

By 27. September 2020#!31Sat, 28 Mar 2026 17:15:58 +0100+01:005831#31Sat, 28 Mar 2026 17:15:58 +0100+01:00-5Europe/Berlin3131Europe/Berlin202631 28pm31pm-31Sat, 28 Mar 2026 17:15:58 +0100+01:005Europe/Berlin3131Europe/Berlin2026312026Sat, 28 Mar 2026 17:15:58 +0100155153pmSaturday=61#!31Sat, 28 Mar 2026 17:15:58 +0100+01:00Europe/Berlin3#March 28th, 2026#!31Sat, 28 Mar 2026 17:15:58 +0100+01:005831#/31Sat, 28 Mar 2026 17:15:58 +0100+01:00-5Europe/Berlin3131Europe/Berlin202631#!31Sat, 28 Mar 2026 17:15:58 +0100+01:00Europe/Berlin3#No Comments

Lesen Sie hier unseren neuesten Artikel aus der European Biotechnology | Autumn Edition | Vol. 19 | 2020

Rainer Krüger, Europäischer Cannabis-Verband und CEO der J&K Consulting GmbH, erklärt, wie Produkt- und Prozessstandards für medizinischen Cannabis festgelegt werden können.

EB_Autumn_2020-ECA-Interview-mit-Cover

Have we sparked your interest and would you like more information?
We are happy to assist you. You can contact us via our Contact page.

Tags: